New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
Abstract
The present invention relates to the CGRP-antagonists of general formula I wherein R 1 , R 2 , R 3 , R 4 and X are defined as in claim 1 , the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I in which one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.
Claims
exact text as granted — not AI-modified1 . A compound of the formula
wherein
X denotes CH 2 , NH, C 1-3 -alkyl-N, O or S,
R 1 denotes a moiety selected from the group consisting of
wherein
R 1.1 denotes H, halogen, HO, F 3 C or C 1-6 -alkyl-O,
R 2 denotes a group of the formulae II
wherein
R 2.1 denotes H, halogen, C 1-3 -alkyl-O, C 1-3 -alkyl or F 3 C,
R 2.2 denotes H, H 2 N, HO, H 3 C—O, H—C(O)—O or C 1-3 -alkyl-C(O)-O,
R 2.3 denotes H, halogen, C 1-3 -alkyl or F 3 C, or
R 2 denotes a moiety selected from the group consisting of
wherein
R 2.4 denotes H or H 3 C,
R 3 denotes a group of the formulae III
wherein
R 3.1 denotes H, C 1-3 -alkyl or R 3.1.1 —(O)C,
R 3.1.1 denotes HO or C 1-6 -alkyl-O,
R 3.2 denotes H or C 1-3 -alkyl and
R 3.3 denotes a free pair of electrons or the oxygen atom,
R 4 denotes a 4- to 7-membered oxycycloalkyl group optionally substituted by R 4.1 and
R 4.1 denotes NC, HO, C 1-3 -alkyl or C 1-3 -alkyl-O,
or a tautomer or salt thereof.
2 . A compound of the formula I according to claim 1 , wherein
X denotes CH 2 , NH or O, R 1 denotes a moiety selected from the group consisting of
wherein
R 1.1 denotes H, Cl, Br, HO, F 3 C or H 3 C—O,
R 2 denotes a group of the formulae II
wherein
R 2.1 denotes H, Cl, Br, H 3 C—O, H 3 C, F 3 C or H 3 C—H 2 C,
R 2.2 denotes H 2 N, HO, H 3 C—O, H—C(O)—O or H 3 C—C(O)—O,
R 2.3 denotes H, Cl, Br, H 3 C or F 3 C, or
R 2 denotes a moiety selected from the group consisting of
wherein
R 2.4 denotes H or H 3 C,
R 3 denotes a group of the formulae III
wherein
R 3.1 denotes H or H 3 C,
R 3.2 denotes H or H 3 C and
R 3.3 denotes a free pair of electrons or the oxygen atom,
R 4 denotes a 4- to 7-membered oxycycloalkyl group optionally substituted by R 4.1 and
R 4.1 denotes HO or C 1-3 -alkyl,
or a tautomer or salt thereof.
3 . A compound of the formula I according to claim 1 , wherein
X denotes CH 2 , NH or O, R 1 denotes a moiety selected from the group consisting of
wherein
R 1.1 denotes H or H 3 C—O,
R 2 denotes a moiety selected from the group consisting of
wherein
R 2.1 denotes H 3 C or F 3 C,
R 2.2 denotes H 2 N or HO,
R 2.4 denotes H or H 3 C,
R 3 denotes a moiety selected from the group consisting of
and
R 4 denotes a moiety selected from the group consisting of
or a tautomer or salt thereof.
4 . A compound of the formula I according to claim 1 , wherein
R 1 denotes a moiety selected from the group consisting of
R 2 denotes a moiety selected from the group consisting of
R 3 denotes a moiety selected from the group consisting of
R 4 denotes a moiety selected from the group consisting of
or a tautomer or salt thereof.
5 . A compound of the formula I according to claim 1 , wherein
R 1 denotes a moiety selected from the group consisting of
R 2 denotes a moiety selected from the group consisting of
R 3 —R 4 together represent a moiety selected from the group consisting of
or a tautomer or salt thereof.
6 . A compound selected from the group consisting of:
No.
Structure
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)
(56)
(57)
(58)
(59)
(60)
(61)
(62)
(63)
(64)
(65)
(66)
(67)
(68)
(69)
(70)
(71)
(72)
(73)
(74)
(75)
(76)
(77)
(78)
(79)
(80)
(81)
(82)
(83)
(84)
(85)
(84a)
(85a)
(86)
(87)
(88)
(89)
(90)
(91)
(92)
(93)
(94)
(95)
(96)
(97)
(98)
(99)
(100)
(101)
(102)
(103)
(104)
(105)
(106)
(107)
(108)
(109)
(110)
(111)
(112)
(113)
(114)
(115)
(116)
(117)
(118)
(119)
(120)
(121)
(122)
(123)
(124)
(125)
(126)
(127)
(128)
(129)
(130)
(131)
(132)
(133)
(134)
(135)
(136)
(137)
(138)
(139)
(140)
(141)
(142)
(143)
(144)
(145)
(146)
(147)
(148)
(149)
(150)
(151)
(152)
(153)
(154)
(155)
(156)
(157)
(158)
(159)
(160)
(161)
(162)
(163)
(164)
(165)
(166)
(167)
(168)
(169)
(170)
(171)
(172)
(173)
(174)
(175)
(176)
(177)
(178)
(179)
(180)
(181)
(182)
(183)
(184)
(185)
(186)
(187)
(188)
(189)
(190)
(191)
(192)
(193)
(194)
(195)
(196)
(197)
(198)
(199)
(200)
(201)
(202)
(203)
(204)
(205)
(206)
(207)
(208)
(209)
(210)
(211)
(212)
(213)
(214)
or a tautomer or salt thereof.
7 . A physiologically acceptable salt of a compound according to claim 1 , 2 , 3 , 4 , 5 or 6 .
8 . A pharmaceutical composition containing a compound according to claim 1 , 2 , 3 , 4 , 5 or 6 or a physiologically acceptable salt thereof together with one or more inert carriers and/or diluents.
9 . A method for the treatment of migraine, cluster headache and tension headache, which comprises the administration to a person suffering from the same a therapeutic amount of a compound according to claim 1 , 2 , 3 , 4 , 5 or 6 or a physiologically acceptable salt thereof together.
10 . A method for the treatment of non-insulin-dependent diabetes mellitus (NIDDM), which comprises the administration to a person suffering from the same a therapeutic amount of a compound according to claim 1 , 2 , 3 , 4 , 5 or 6 or a physiologically acceptable salt thereof together.
11 . A method for the treatment of cardiovascular diseases, morphine tolerance, diarrhoea caused by clostridium toxin, skin diseases, particularly thermal and radiation-induced skin damage including sunburn, lichen, prurigo, pruriginous toxidermies and severe itching, inflammatory diseases, e.g. inflammatory diseases of the joints such as osteoarthritis, rheumatoid arthritis or neurogenic arthritis, generalised soft tissue rheumatism (fibromyalgia), neurogenic inflammation of the oral mucosa, inflammatory lung diseases, allergic rhinitis, asthma and COPD, diseases accompanied by excessive vasodilatation and resultant reduced blood supply to the tissues, e.g. in particular shock and sepsis, chronic pain, such as e.g. diabetic neuropathies, neuropathies induced by chemotherapy, HIV-induced neuropathies, post-herpetic neuropathies, neuropathies induced by tissue trauma, trigeminal neuralgias, temporomandibular dysfunctions, CRPS, back pain and visceral diseases such as for example IBS (irritable bowel syndrome) or inflammatory bowel syndrome, for relieving pain in general or for the preventive or acute therapeutic treatment of the symptoms of hot flushes caused by vasodilatation and increased blood flow in menopausal oestrogen-deficient women and hormone-treated patients with prostate carcinoma and castrated men, which comprises the administration to a person suffering from the same a therapeutic amount of a compound according to claim 1 , 2 , 3 , 4 , 5 or 6 or a physiologically acceptable salt thereof together.Join the waitlist — get patent alerts
Track US2010144716A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.